therapies to conventional levodopa and levodopa/carbidopa combinations. Both agents seem to signifi cantly increase 'on' time in PD patients who are experiencing reemergence of motor symptoms, they afford greater functionality than conventional levodopa and combinations alone, and they are generally well tolerated. It is suggested that patients who experience motor fl uctuations despite ongoing treatment with conventional levodopa, dopamine agonists or MAO-B inhibitors should receive a trial with a COMT inhibitor and certainly before levodopa infusion or neurosurgery are considered as last resort strategies.
Many PD patients experience neuropsychiatric illnesses such as anxiety and depression. Depression is particularly diffi cult to diagnose in PD patients because of the overlap of many of the cognitive, motor and somatic symptoms (Looi et al 2005; Frisina 2008 ). PD patients, even when suffering from affective disturbances, are more likely to complain about their burden of motor disability. Nevertheless, depression seems to occur in about 30%-40% of PD patients, of whom only one-fi fth receive any form of antidepressant treatment. In this issue, Frisina and her colleagues (2008) discuss the health risks, etiology, and treatment options for depression in PD patients. It seems that conventional treatments are effective, and they recommend a multidisciplinary approach combining pharmacotherapy, psychotherapy, and psychoeducation.
PD is a complex disease but there are many therapeutic possibilities to relieve the burden of both the motor and some of the nonmotor symptoms. All of the current pharmacotherapies are symptomatic, and only neurosurgery goes to the heart of the neuropathology. However, most PD patients can be reliably maintained on a judiciously tailored and regularly monitored set of medications. Advances in our understanding of the pathogenesis of the disease, particularly the rapidly expanding fi eld of PD genetics, may lead to more specifi c and potentially disease modifying modalities in the future. Whatever, on the basis of current and extensive evidence in clinical trials and despite its many shortcomings, levodopa in its several forms remains the gold standard of effi cacy and effectiveness in PD therapeutics.
